Decision about the optimal timing of a treatment procedure in patients with hematologic neoplasms is critical, especially for cellular therapies (most including allogeneic hematopoietic stem-cell ...
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced the first published validation study to evaluate the performance of optical genome mapping (OGM) versus ...
Patients with multiple myeloma (MM) have a distinct pattern of second primary malignancy (SPM), with a markedly increased risk of hematologic SPMs, according to a review published online April 6 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results